Viiv Healthcare

This study is testing a new oral medication, VH4524184, for adults who have never taken HIV treatment before. Researchers want to see if taking VH4524184 with two other standard HIV drugs works as well as or better than a current standard treatment combination. The main goal is t…

This early-stage study is testing an experimental drug, VH3810109, to see if it can reduce the hidden, inactive HIV that persists in the body even with standard treatment. It will involve 100 adults living with HIV, including some just starting treatment and others who have been …

This study is testing a long-acting, injectable HIV treatment for people whose current daily pill regimen is not fully controlling the virus. About 332 participants will be randomly assigned to receive either the new monthly injections or continue their standard oral medication. …

This early-stage study is testing a new long-acting injectable drug called VH4524184 for HIV treatment. Researchers are giving different doses to healthy adults to check if it's safe and how long it stays in the body. The goal is to find a dose that could eventually allow people …

This is an early safety study testing new, long-acting injectable versions of HIV medications called cabotegravir and rilpivirine. Researchers are giving single injections to healthy adult volunteers to see how safe they are and to measure how long the drugs stay active in the bo…

This study follows people at risk of HIV who previously participated in trials for a long-acting preventive injection called cabotegravir (CAB LA). The goal is to monitor the long-term safety and continued effectiveness of the injection in preventing new HIV infections. Participa…

This is an early-stage study to check the safety and body processing of a new long-acting injection, VH4011499, intended to help prevent HIV. It involves 168 healthy adults without HIV who will receive single or multiple shots. The main goal is to see how well the drug is tolerat…